BRAF and lung carcinoma: Similarly, MEK inhibition in KRAS-mutant lung cancer A549 cells and BRAF inhibition in BRAF-mutant melanoma A375 cells also increased IRF1 and IFIT1 protein levels (Fig. 2d, right).